Goldman Sachs analyst David Roman maintained a Hold rating on Kestra Medical Technologies Ltd. today and set a price target of $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Roman has given his Hold rating due to a combination of factors surrounding Kestra Medical Technologies Ltd.’s recent performance and future outlook. The company’s 4QFY25 revenue showed a significant year-over-year increase and exceeded expectations, driven by a rise in prescriptions and improved revenue cycle management. However, despite these positive developments, the company reported a larger-than-expected EBITDA loss, indicating higher investments in its commercial strategy.
Furthermore, while Kestra’s guidance for FY2026 suggests continued revenue growth, the market environment remains challenging with moderate growth expectations. The company’s gross margins have improved, yet the overall financial returns and market conditions warrant a cautious approach. Therefore, considering these mixed signals, David Roman has opted for a Hold rating, reflecting a balanced view of potential risks and opportunities.